- Details
- In this UroToday Journal Club video, Drs Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication "Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer". This work aimed to assess the association between treatment approach, functional outcomes, patient expectations, and treat...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled “Differential Activity of PARP Inhibitors in BRCA1-Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.” Olaparib and Rucaparib are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations. This data aimed to study the relativ...
|
- Details
- In this UroToday journal club, Christopher Wallis and Zachary Klaassen highlight a European Urology Focus publication entitled Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States. Blue light cystoscopy (BLC) for the management of nonmuscle invasive bladder cancer (NMIBC) is an evidence- and guideline-supported intervention that has been shown to increase cancer detect...
|
- Details
- Christopher Wallis and Zachary Klaassen review the 2022 NCCN Clinical Practice Guideline in Oncology Prostate Cancer reviewing the epidemiology, initial diagnosis, and life expectancy of men with prostate cancer. Dr. Klaassen provides an overview of prostate cancer epidemiology, details the initial prostate cancer diagnosis, and highlights the importance of estimating life expectancy in these pati...
|
- Details
- Christopher Wallis and Zachary Klaassen review the NCCN Clinical Practice Guideline in Oncology Prostate Cancer and in this conversation the pair focuses on nuances in advanced prostate cancer, including neuroendocrine disease, bone, and visceral metastases, and treatment sequencing. In the context of bone metastases, Dr. Wallis highlights a variety of data that has been published over the last fe...
|
- Details
- In this UroToday Journal Club presentation Christopher Wallis and Zachary Klaassen, continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer. Dr. Christopher Wallis discusses the use of nomograms and the use of Tumor Multigene Molec...
|
- Details
- In this UroToday presentation Christopher Wallis and Zachary Klaassen, continue their discussion on the NCCN prostate cancer clinical practice guidelines in oncology focusing on observation and Active Surveillance (AS). The AS section of the NCCN Guidelines includes an introduction, the rationale, patient selection, confirmatory testing by discussion of an Active Surveillance program, as well as r...
|
- Details
- Christopher Wallis and Zachary Klaassen, continue their discussion on the NCCN clinical practice guidelines in oncology focusing on prostate cancer and the recently released and published update of these guidelines from September 2021. In this conversation the pair focus on questions relating to the initial clinical assessments, staging evaluation, and imaging approaches in prostate cancer. Biogra...
|
- Details
- The UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen discuss the NCCN clinical practice guidelines in oncology focusing on prostate cancer genetics. To set the stage for discussing prostate cancer genetics, they start with a background on genetics and then focus on three specific aspects of prostate cancer genetics, namely homologous recombination repair, DNA mismatc...
|
- Details
- In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part two of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...
|
